Search

Ces dernières années, le domaine des biomarqueurs du mélanome a suscité un intérêt croissant, avec une attention particulière pour le candidat prometteur ADN tumoral circulant (ADNtc). Cependant, en milieu adjuvant, des incertitudes persistent quant à la pertinence de l’ADNtc pour les évaluations pronostiques.

Despite advances in multidisciplinary approaches, the prognosis for most patients with malignant gliomas is poor. Malignant gliomas are highly vascularized tumors with elevated expression of vascular endothelial growth factor (VEGF), an important mediator of angiogenesis. Recent studies of bevacizumab, an anti-VEGF monoclonal antibody, alone or associated with chemotherapy, have demonstrated high response rates and prolongation of median and 6-month progression-free survival. Clinical evaluation of several multitarget small molecule tyrosine kinase inhibitors is ongoing. Other promising antiangiogenic compounds are cilengitide and continuous temozolomide. Toxicity is acceptable. Open issues are represented by patterns of tumor progression, resistance mechanisms and biomarkers.